Trial Profile
Phase II study of sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naive (extensive disease) or have a "sensitive" relapse.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jul 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Fludeoxyglucose F-18
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 30 Jul 2021 This trial has been completed in Spain as reported by European Clinical Trials Databa (end of the trial 2012-08-27).
- 12 Dec 2015 Results (n=9), published in the European Journal of Cancer.
- 14 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.